Global Pandemic Control Markets and Technologies


Published on

Buy the report "Global Markets and Technologies for Pandemic Control" at US $5450 for a Single User PDF License from RnR Market Research Reports Library.An overview of the products in development to treat bacterial diseases, especially those caused by drug-resistant organisms, and HIV/AIDS

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Global Pandemic Control Markets and Technologies

  1. 1. RnR Market Research Offers “Global Markets and Technologies for Pandemic Control”Report at US$ 5450 (Single User License). The report got published in Mar 2013 &Contain 172 Pages.The report provides:- An overview of the products in development to treat bacterial diseases, especially those caused bydrug-resistant organisms, and HIV/AIDS- Analyses of market trends, with data from 2011 and 2012, and projections of compound annual growthrates (CAGRs) through 2017- Clarification of the HIV/AIDS pandemic and ongoing efforts to control it- Discussion of emerging threats, such as multidrug-resistant tuberculosis, West Nile virus and otherserious viral diseases- Trends based on projected sales through 2017 for new products, including supporting analyses forprojections.- Comprehensive company profiles of major players.IntroductionReasons for Doing the StudyThe spread of human immunodeficiency virus (HIV), hepatitis B and C, evolving influenza strains andantibiotic-resistant organisms have put healthcare agencies on guard to avert pending pandemics fromthese diseases. They have also alerted healthcare professionals to the possibility of the use of virusesand bacteria in bioterrorism threats.The problem of antimicrobial resistance poses a global threat to the effective treatment of many bacterialdiseases. Additionally, the emergence of drug-resistant strains of HIV and hepatitis have jolted thehealthcare community out of its relative complacency about the threat of infectious diseases andprompted diagnostic and pharmaceutical manufacturers to bolster their infectious disease pipelines.Multidrug-resistant tuberculosis is no longer confined to any one country or to those individuals who areco-infected with HIV. A number of multidrug resistant microbes such as methicillin-resistantStaphalococcus auerus (MRSA) and vancomycin-resistant Enterococcus (VRE) that were once foundonly in hospitals or nursing homes are now active in the community at large.The rate of HIV infection combined with resistance to existing HIV and acquired immunodeficiencysyndrome (AIDS) drugs and the obstacles encountered in developing an AIDS vaccine have resulted in afull-blown pandemic. Further, drug resistance in the treatment of HIV/AIDS necessitates the use ofcomplex dosage protocols with unpleasant side effects that often further debilitate patients.Solutions to the dilemma of drug resistance involve management approaches on a worldwide scale (suchas the implementation of rigorous surveillance of resistant organisms), better education of healthcareworkers about appropriate use of antibiotics and closer monitoring of antibiotics used in animal and plantcrops.Combined with these organizational activities is the need for new and effective drugs. New drugs to treatbacterial diseases and HIV/AIDS are being developed, but a new class of drugs to treat bacterialinfections has not been developed since 2003, underscoring the need for more development in this area.Get Report Details @
  2. 2. Scope Of ReportThis report provides an in-depth look at the emerging pandemic of antibiotic resistance and theestablished viral pandemic of HIV/AIDS. It also provides historical, epidemiological and marketinformation on hepatitis B and C, tuberculosis and malaria. This report also investigates bacterial and viraldiseases that are emerging as health threats because of inadequate or nonexistent preventive and/ortherapeutic products to combat them.Antibiotic-resistant organisms wreak havoc with international healthcare systems as methicillin-resistantStaphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE) and Clostridium difficile (C.diffile) become more pervasive. These infections represent future pandemics if no suitable antibiotics aredeveloped to counteract them. At present, each is problematic, but remains at an epidemic level, primarilywithin healthcare institutions and nursing facilities. Consequently, these infections are covereddescriptively within the report, but are not yet classified as pandemics, nor measured quantitatively aspart of the overall market for pandemics.The report outlines the available preventative and diagnostic products used to combat current and futurepandemic infections and projects markets for these products. Forecasts are provided for the diagnosticand pharmaceutical markets for products to treat HIV/AIDS, hepatitis B and C, malaria and tuberculosis.Forecasts and trends are gleaned from industry sources as well as from an assessment of emergingproducts and technologies.The causes, the extent of impact and strategies to monitor, treat and prevent resistant diseases areassessed. The mechanisms by which drugs function to combat resistant microbes are described. Drugsthat show promise of long-term activity (i.e., low likelihood of resistance) and their effects on the marketare assessed.Methodology/Information SourcesThe data for this report were gathered from primary and secondary sources, including informationobtained from industry analysts, manufacturer and company reports, industry trade journals, medicaljournals and industry associations. Additional information was obtained through the U.S. Patent andTrademark Office (USPTO), U.S. Securities and Exchange Commission (SEC) filings, The World HealthOrganization (WHO), the Organisation for Economic Cooperation and Development (OECD), the MayoClinic, the Pharmaceutical Research and Manufacturing Association and the Joint United NationsProgramme on HIV/AIDS (UNAIDS).Where precise information was not available, projections were made using reasonable assumptions andestimates based on historical data. Market data are based on manufacturers’ sales.Inquiry For Discount @ of ContentChapter- 1: IntroductionReasons for Doing the StudyScope of ReportMethodology/Information SourcesIntended AudienceAnalyst CredentialsRelated Bcc Reports
  3. 3. Bcc Online ServicesDisclaimerChapter- 2: SummaryTable Summary : Projected Market for Pandemic Infectious Disease Products, by Disease Type, Through2017Figure Summary : Projected Market for Pandemic Infectious Disease Products, by Region, 2012 and2017Chapter- 3: OverviewPathogenic Microbes and Infectious Diseases Recognized Between 1973 and 2009Factors In the Emergence of Infectious DiseasesAntibiotic DevelopmentClassifying Viral Outbreaks, Epidemics and PandemicsCurrent and Potential Epidemics With Pandemic PotentialCurrent and Potential PandemicsCurrent Technologies for Addressing Potential Pandemic ThreatsBiological Weapons for TerrorismA Brief History of Global PandemicsTreatments for Infectious DiseasesOpportunities to Fight Potential Pandemic Infectious DiseasesBioinformation and Remote Sensing MarketMergers and AcquisitionsChapter- 4: Vaccines, Diagnostic Testing, and Pharmaceutical Markets for Infectious DiseasesVaccinesTypes of Diagnostic TestingMarket Analysis, by DiseaseChapter- 5: Disease OverviewAnthraxCholeraHepatitis B and CHiv/AidsInfluenzaMalariaSevere Acute Respiratory Syndrome (Sars)TuberculosisHemorrhagic FeversTable 27 : Causative Organisms for Pandemic DiseasesChapter- 6: Viral Pandemic Threats and TreatmentsWhat Is A Virus?Projected Global Market for Vaccines, Diagnostics and PharmaceuticalsGlobal Diagnostic Market for Hiv and HepatitisMarket for Viral Disease Diagnostic ProductsViral Pandemic Pharmaceutical Products, by DiseaseHepatitisRegional AnalysisAmericasEmraAsiaOpportunities In the Viral Pandemic Infectious Disease Diagnosis and Treatment MarketChapter- 7: Bacterial Pandemic Threats and TreatmentsAntibacterial ResistancePrimary Reasons for Antibiotic ResistanceSurveillance of Microbial Resistance to Antibiotics
  4. 4. Resistance by Class of AntibioticIncidences of Antibiotic ResistanceVancomycin-Resistant Enterococcus (Vre)Methicillin-Resistant Staphylococcus Aureus (Mrsa)Clostridium Difficile (C. Difficile)Tuberculosis (Tb)Regional AnalysisOpportunities In the Tuberculosis MarketChapter- 8: Parasitic Pandemic Threats and TreatmentsClimate Change and Vector-Borne DiseasesChapter- 9: RegulationsCreating Drug TreatmentsRegional RegulationsChapter- 10: Pharmaceutical Treatment PipelineEmerging Trends In Diagnostic ProductsEmerging Trends In Pharmaceutical ProductsPharmaceutical Treatment Product PipelineChapter- 11: Patent AnalysisPharmaceutical Patents Issued by Company, Approval Date and DiseaseDiagnostic Patents Issued by Company, Approval Date and DiseasePatents Issued by CompanyPatents Issued by CountryPatents Issued, by DiseaseChapter- 12: Company DirectoryAbbott LaboratoriesAlereAlfa Scientific DesignsAnadys Pharmaceuticals (See Roche)Atlas Link Biotech Co, LtdBaxter HealthcareBayer AgBio-Rad LaboratoriesBoehringer Ingelheim GmbhBristol-Myers Squibb CompanyCreative DiagnosticsDiagnostic Automation/Cortez Diagnostics, IncDiasorinEmergent BiosolutionsEnanta PharmaceuticalsEnzo BiochemFirst Diagnostic LlcGilead Sciences, Inc.GlaxosmithklineHome Access Health, IncHuman Genome Sciences (See Glaxosmithkline)Idenix PharmaceuticalsImmunosticsInd Diagnostic, Inc.Inverness Medical Innovations (See Alere)Janssen Therapeutics (Formerly Tibotec Therapeutics)Merck & Company, Inc.Novartis Pharmaceutical Corporation
  5. 5. Orasure Technologies, Inc.Ortho Clinical DiagnosticsPfizer, Inc.Princeton Biomeditech CorporationProtein Sciences CorporationRoche Laboratories (Hoffmann-La Roche Inc)Rib-X PharmaceuticalsRomark LaboratoriesSanofi PasteurSciclone PharmaceuticalsShanghai Kehua Bio-Engineering Co, LtdStandard Diagnostics, IncTrinity Biotech PlcVertex PharmaceuticalsViiv HealthcareFor more details contact Mr. Priyank Tiwari: / +18883915441Website: